Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Expensive Rocket
3345.3000 -2.20 (-0.07%)
NSE Jul 02, 2026 15:31 PM
Volume: 76,713
 

logo
Ajanta Pharma Ltd.
27 Oct 2016
3345.30
-0.07%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 18% YoY to | 516 crore (I-direct estimate: | 513 crore) on back of 21% growth in domestic sales to | 158 crore (Idirect estimate: | 155 crore). Export formulation grew 14% to | 345 crore (I-direct estimate: | 339 crore) on a sharp jump in US sales. US sales rose to | 71 crore vs. | 2 crore, | 10 crore in Q2FY16, Q1FY17, respectively. Asia, Africa sales, on the other hand, were muted EBITDA margins declined 157 bps to 33.6% (I-direct estimates: 34.0%) mainly due to forex loss of | 9.84 crore...
Ajanta Pharma has gained 33.67% in the last 1 Year
More from Ajanta Pharma Ltd.
Recommended